Novo Nordisk Sickle Cell Drug Reduced Complications in Trial

Novo Nordisk A/S said patients who took its experimental sickle cell disease drug etavopivat had roughly half as many vaso-occlusive events as those who took placebo after a year of use, in data presented at the ASH conference in San Diego.

• Patients on experimental treatment experienced first complications at an average of 34 weeks, compared with 17 weeks for placebo group
• Results are from 60 patients in phase 2 trial Hibiscus
• Novo will continue to test etavopivat in a large phase 3 trial and, if successful, anticipates being able to seek regulatory approval for the drug in 2026, development chief ...